Dianthus Therapeutics Target of Unusually Large Options Trading (NASDAQ:DNTH)

Key Points

• Dianthus Therapeutics experienced a significant increase in options trading, with 6,850 call options traded, marking a 1,493% surge from its average volume.
• Recent analyst ratings show a consensus of buy on the stock, with target prices ranging from $40.00 to $54.00, indicating positive investor sentiment.
• Despite reporting an earnings miss with a loss of ($0.88) EPS, the company is actively developing therapies for severe autoimmune diseases, including a monoclonal antibody currently in Phase 2 clinical trials.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) saw some unusual options trading on Monday. Stock traders acquired 6,850 call options on the stock. Thisrepresentsanincreaseof1,493% compared to the average volume of 430 call options.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday. Wedbush lifted their target price on Dianthus Therapeutics from $34.00 to $42.00 and gave the company an "outperform" rating in a research report on Thursday, August 21st. Robert W. Baird lowered their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Finally, William Blair started coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $54.00.

Dianthus Therapeutics Price Performance

Shares of DNTH traded up $5.30 during mid-day trading on Monday, reaching $31.80. 5,958,850 shares of the company's stock traded hands, compared to its average volume of 359,873. The stock has a market cap of $1.02 billion, a P/E ratio of -9.78 and a beta of 1.46. The stock's 50-day moving average is $21.27 and its two-hundred day moving average is $20.03. Dianthus Therapeutics has a 12 month low of $13.36 and a 12 month high of $32.80.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of DNTH. Vestal Point Capital LP lifted its holdings in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after buying an additional 1,499,931 shares during the period. RA Capital Management L.P. lifted its holdings in Dianthus Therapeutics by 53.6% during the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock worth $52,003,000 after buying an additional 1,000,333 shares during the period. Octagon Capital Advisors LP lifted its holdings in shares of Dianthus Therapeutics by 20.8% during the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after purchasing an additional 363,500 shares during the last quarter. Candriam S.C.A. purchased a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at $4,510,000. Finally, Alliancebernstein L.P. lifted its holdings in shares of Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock valued at $21,887,000 after purchasing an additional 149,200 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.